Compare GGR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | PYXS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.6M | 71.6M |
| IPO Year | N/A | 2021 |
| Metric | GGR | PYXS |
|---|---|---|
| Price | $3.38 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 22.5K | ★ 2.5M |
| Earning Date | 02-12-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,211,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.83 |
| 52 Week High | $10.15 | $5.55 |
| Indicator | GGR | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 41.92 |
| Support Level | $2.96 | $1.03 |
| Resistance Level | $3.37 | $2.17 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 86.75 | 66.22 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.